


THE WHY AND HOW FOR COMBINATION BASAL INSULIN + GLP-1RA THERAPY IN TYPE 2 DIABETES



REFERENCES

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. *JAMA*. 1979;241(19):2035-2038.
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321(7258):405-412.
3. Sun X, Du T. Trends in cardiovascular risk factors among U.S. men and women with and without diabetes, 1988-2014. *BMC Public Health*. 2017;17(1):893.
4. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *Lancet*. 2010;375(9724):1447-1456.
5. Singhal M, Nguyen H, Schauerhamer M, Unni S, Cobden D, McAdam-Marx C. Effect of daily or weekly GLP-1 receptor agonists on glycemic control in insulin-naive patients with poorly controlled type 2 diabetes: A real-world study. ISPOR 20th Annual International Meeting; May 2015; Philadelphia, PA.
6. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. *Lancet*. 2009;373(9662):473-481.
7. Farr AM, Sheehan JJ, Curkendall SM, Smith DM, Johnston SS, Kalsekar I. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. *Adv Ther*. 2014;31(12):1287-1305.
8. Zhou FL, Xie L, Pan C, et al. Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin. *Diabetes Obes Metab*. 2018;20(5):1298-1301.
9. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. *Diabetes Care*. 2001;24(6):1069-1078.
10. Hermanns N, Kulzer B, Krichbaum M, Kubiak T, Haak T. Affective and anxiety disorders in a German sample of diabetic patients: prevalence, comorbidity and risk factors. *Diabet Med*. 2005;22(3):293-300.
11. Holt RI, de Groot M, Golden SH. Diabetes and depression. *Curr Diab Rep*. 2014;14(6):491.
12. Perrin NE, Davies MJ, Robertson N, Snoek FJ, Khunti K. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. *Diabet Med*. 2017;34(11):1508-1520.
13. American Diabetes Association. Standards of Medical Care in Diabetes- 2018. *Diabetes Care*. 2018;41(Suppl 1):S1-S159.
14. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm- 2018 Executive Summary. *Endocr Pract*. 2018;24(1):91-120.
15. Bolen S, Tseng E, Hutfless S, et al. AHRQ Comparative Effectiveness Reviews. In: *Diabetes Medications for Adults With Type 2 Diabetes: An Update*. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016: <https://effectivehealthcare.ahrq.gov/topics/diabetes-update-2015/research/>. Accessed February 2, 2018.
16. Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. *Diabetes Obes Metab*. 2013;15(6):485-502.
17. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2017;377(13):1228-1239.
18. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375(4):311-322.
19. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. *N Engl J Med*. 2015;373(23):2247-2257.
20. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375(19):1834-1844.
21. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017;377(7):644-657.
22. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373(22):2117-2128.

23. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012;367(4):319-328.
24. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. *N Engl J Med*. 2017;377(8):723-732.
25. Reid T, Gao L, Gill J, et al. How much is too much? Outcomes in patients using high-dose insulin glargine. *Int J Clin Pract*. 2016;70(1):56-65.
26. Little S, Shaw J, Home P. Hypoglycemia rates with basal insulin analogs. *Diabetes Technol Ther*. 2011;13(Suppl 1):S53-64.
27. Cohen ND, Audehm R, Pretorius E, Kaye J, Chapman LH, Colagiuri S. The rationale for combining GLP-1 receptor agonists with basal insulin. *Med J Aust*. 2013;199(4):246-249.
28. Carris NW, Taylor JR, Gums JG. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. *Drugs*. 2014;74(18):2141-2152.
29. Maiorino MI, Chiodini P, Bellastella G, Capuano A, Esposito K, Giugliano D. Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. *Diabetes Care*. 2017;40(4):614-624.
30. Diamant M, Nauck MA, Shaginian R, et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. *Diabetes Care*. 2014;37(10):2763-2773.
31. Holst JJ, Vilsboll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. *Diabetes Obes Metab*. 2013;15(1):3-14.
32. Vora J. Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. *Diabetes Care*. 2013;36(Suppl 2):S226-232.
33. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. *Diabet Med*. 2012;29(5):682-689.
34. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. *Diabetes Care*. 2010;33(2):240-245.
35. Xultophy 100/3.6 [package insert]. In. Plainsboro, NJ: Novo Nordisk Inc.; 2016.
36. Soliqua 100/33 [package insert]. In. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2018.
37. Gough SC, Bode BW, Woo VC, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. *Diabetes Obes Metab*. 2015;17(10):965-973.
38. Buse JB, Vilsboll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). *Diabetes Care*. 2014;37(11):2926-2933.
39. Linjawi S, Bode BW, Chaykin LB, et al. The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a glp-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. *Diabetes Ther*. 2017;8(1):101-114.
40. Lingvay I, Harris S, Jaeckel E, Chandarana K, Ranthe MF, Jodar E. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. *Diabetes Obes Metab*. 2018;20(1):200-205.
41. Billings LK, Doshi A, Gouet D, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The DUAL VII randomized clinical trial. *Diabetes Care*. 2018;41(5):1009-1016.
42. Lingvay I, Perez Manghi F, Garcia-Hernandez P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycosylated hemoglobin levels in patients with uncontrolled type 2 diabetes: The DUAL V randomized clinical trial. *JAMA*. 2016;315(9):898-907.
43. Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: The LixiLan-O randomized trial. *Diabetes Care*. 2016;39(11):2026-2035.
44. Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial. *Diabetes Care*. 2016;39(11):1972-1980.
45. Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. *Lancet Diabetes Endocrinol*. 2014;2(11):885-893.